tetra-o-methyl nordihydroguaiaretic acid
Small moleculeexperimental
Clinical trial activity
7 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2003 (NCT00057512)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Brain Neoplasms · Phase 1/Phase 2
- Cervical Intraepithelial Neoplasia · Phase 1/Phase 2
- Glioma · Phase 1
- Head and Neck Neoplasms · Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Lymphoma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis.
Binds to the DNA major groove of specific Sp1 DNA binding domains within gene promoter regions.
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C[C@@H](C)[C@@H](C)Cc2ccc(OC)c(OC)c2)cc1OC- Mol. weight
- 358.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL90983 ↗
Also known as
- 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-dimethoxybenzene
- em-1421
- em-1421
- em-1421
- fw 358.2
- fw-358.2
- terameprocol
- terameprocol
- terameprocol
- terameprocol
- terameprocol
- tetramethoxynordihydroguaiaretic acid
- tetra-o-methyl-ndga
- tetra-o-methyl nordihydroguaiaretic acid
- tetra-o-methyl nordihydroguaiaretic acid
- tetra-o-methylnordihydroguaiaretic acid
- tmndga
- tmndga
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02575794 | Phase 1 | Nov 15, 2017 | American Board for Transplant Certification, Erimos Pharmaceuticals, Johns Hopkins University |
| NCT00664677 | Phase 1 | Aug 1, 2007 | Erimos Pharmaceuticals |
| NCT00664586 | Phase 1 | May 1, 2007 | Erimos Pharmaceuticals |
| NCT00404248 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2007 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00259818 | Phase 1 | Dec 1, 2005 | Erimos Pharmaceuticals |
| NCT00154089 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2004 | Erimos Pharmaceuticals, Planned Parenthood, University of Maryland |
| NCT00057512 | Phase 1 | Jan 1, 2003 | Duke University, Erimos Pharmaceuticals, Medical University of South Carolina |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Erimos Pharmaceuticals | For profit | 6 | 5 | 2 | 2003 |
| Johns Hopkins University | Academic/Hospital | 2 | 2 | 2 | 2007 |
| American Board for Transplant Certification | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2003 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2007 |
| Planned Parenthood | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2004 |
8 organizations
Page 1 / 1